Mutant, wild type, or overall p53 expression: Freedom from clinical progression in tumours of astrocytic lineage

British Journal of Cancer

Volumn 91, Issue 9, 2004, Pages 1678-1686

  Pardo, F S ^a,b,c,h   Hsu, D W ^b   Zeheb, R ^d   Efird, J T ^a,e   Okunieff, P G ^b,c,f   Malkin, D M ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Oncogene Science Inc   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h NONE   (United States)

Author keywords

Brain tumour; Glioma survival; Radiation therapy

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PROTEIN P53;

ACTUARIAL SURVIVAL; ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; ASTROCYTE; BRAIN TUMOR; CANCER CELL CULTURE; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CELL LINEAGE; DNA SEQUENCE; EXON; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENERAL HOSPITAL; GLIOMA; GLIOMA CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT FAILURE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; WILD TYPE;

ASTROCYTOMA; CELL LINEAGE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MASSACHUSETTS; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9144223738     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602161     Document Type: Article

References (59)

1. Agami R, Bernards R (2000) Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 102: 55-66
2. Agarwal ML, Agarwal A, Taylor WR, Stark GR (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493-8497
3. Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives G (1991) Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65: 1083-1091
4. Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, Leigh IM, Purkis T, MacGeoch C, Spurr NK, Bartek J, Vojtesek B, Picksley SM, Lane DP (1992) Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 340: 259-263
5. Bowker A, Lieberman G (1972) Engineering Statistics. Prentice-Hall: NJ
6. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold Jr SC, Bullard DE (1987) Clinicopathologic correlations in the oligodendroglioma. Cancer 59: 1345-1352
7. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB, Aldape KD (2002) Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 8: 180-187
8. Calogero A, Lombari V, De Gregorio G, Porcellini A, Ucci S, Arcella A, Caruso R, Gagliardi FM, Gulino A, Lanzetta G, Frati L, Mercola D, Ragona G (2004) Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma. Cancer Cell Int 4: 1
9. Carozza SE, Wrensch M, Miike R, Newman B, Olshan AF, Savitz DA, Yost M, Lee M (2000) Occupation and adult gliomas. Am J Epidemiol 152: 838-846
10. Chen PC, Aldape K, Wiencke JK, Kelsey KT, Miike R, Davis RL, Liu J, Kesler-Diaz A, Takahashi M, Wrensch M (2001) Ethnicity delineates different genetic pathways in malignant glioma. Cancer Res 61: 3949-3954
11. Chozick BS, Pezullo JC, Epstein MH, Finch PW (1994a) Prognostic implication of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35: 831-838
12. Chozick BS, Weicker ME, Pezzullo JC, Jackson CL, Finkelstein SD, Ambler MW, Epstein MH, Finch PW (1994b) Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 73: 406-415
13. Cobbs CS, Whisenhunt TR, Wesemann DR, Harkins LE, Van Meir EG, Samanta M (2003) Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res 63: 8670-8673
14. Cox DR (1993) Regression models and life-tables. J R Stat Soc Bull 34: 187-220
15. Dai S, Huang ML, Hsu CY, Chao KS (2003) Inhibition of hypoxia inducible factor 1alpha causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys 55: 1027-1036
16. Das A, Tan WL, Teo J, Smith DR (2002) Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway. J Neurooncol 60: 117-125
17. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62: 2152-2165
18. de Toledo SM, Azzam EL, Keng P, Laffrenier S, Little JB (1998) Regulation by ionizing radiation of CDC2, cyclin A, cyclin B, thymidine kinase, topoisomerase IIalpha, and RAD51 expression in normal human diploid fibroblasts is dependent on p53/p21Waf1. Cell Growth Differ 9: 887-896
19. Debbas M, White E (1993) Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7: 546-554
20. Denko NC, Green SL, Edwards D, Giaccia AJ (2000) p53 checkpoint-defective cells are sensitive to X rays, but not hypoxia. Exp Cell Res 258: 82-91
21. Dulic V, Kaufmann WK, Wilson SJ, Tisty TD, Lees E, Harper JW, Elledge SJ, Reed SI (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023
22. Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR (1994) Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 69: 26-31
23. Frankel RH, Bayona W, Koslow M, Newcomb EW (1992) p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 52: 1427-1433
24. Fujimaki T, Matsutani M, Nakamura O, Asai A, Funada N, Koike M, Segawa H, Aritake K, Fukushima T, Houjo S, Tamura A, Sano K (1991) Correlation between bromodeoxyuridine-labeling indices and patient prognosis in cerebral astrocytic tumors of adults. Cancer 67: 1629-1634
25. Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602
26. Ghimenti C, Fiano V, Chiado-Piat L, Chio A, Cavalla P, Schiffer D (2003) Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets 77. J Neurooncol 61: 95-102
27. Iuzzolino P, Ghimenton C, Nicolato A, Giorgiutti F, Fina P, Doglioni C, Barbareschi M (1994) p53 protein in low grade astrocytomas: a study with long-term follow-up. Br J Cancer 69: 586-591
28. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
29. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E (1997) MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 75: 1269-1278
30. Korkolopoulou P, Kouzelis K, Christodoulou P, Papanikolaou A, Thomas-Tsagli E (1998) Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathol (Berl) 95: 617-624
31. Krishnan G, Felini M, Carozza SE, Miike R, Chew T, Wrensch M (2003) Occupation and adult gliomas in the San Francisco Bay Area. Journal of Occupational and Environmental Medicine 45: 637-647
32. Kurtkaya-Yapicier O, Scheithauer BW, Hebrink D, James CD (2002) p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study. Neurosurgery 51: 1246-1254
33. Lowe SW, Ruley HE (1993) Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7: 535-545
34. Malmer B, Brannstrom T, Andersson U, Bergh K, Gronberg H, Henriksson R (2002) Does a low frequency of P53 and Pgp expression in familial glioma compared to sporadic controls indicate biological differences? Anticancer Res 22: 3949-3954
35. Mashuyama S, Murikami Y, Yoshimoto T, Sekiya T, Hayashi K (1991) Detection of p53 gene mutation in human brain tumors by single strand confinement polymorphism: analysis of polymerase chain-reaction products. Oncogens 6: 1313-1318
36. Mawrin C, Lins H, Kirches E, Schildhaus HU, Scherlach C, Kanakis D, Dietzmann K (2003) Distribution of p53 alterations in a case of gliomatosis cerebri 84. Hum Pathol 34: 102-106
37. Miettinen HE, Paunu N, Rantala I, Kalimo H, Paljarvi L, Helin H, Haapasalo H (2001) Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique. J Neurooncol 55: 29-37
38. Morita M, Rosenblum MK, Bilsky MH, Fraser RAR, Rosenfeld MR (1996) Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neuro Oncol 27: 259-266
39. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD (2001) Papillomavirus type 16 oncogenes downregulate expression of interferon- responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 75: 4283-4296
40. Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL, Louis DN (2003) Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res 63: 413-416
41. Pardo FS, Aronen HG, Kennedy D, Skates S, Paiva K, Okunieff P, Schmidt EV, Hochberg FH, Harsh GR, Fischman AJ, Linggood RM, Rosen BR (1994) Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. Int J Rad Oncol Biol Phys 30: 663-669
42. Pollack IF, Finkelstein SD, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Finlay JL, Sposto R (2001) Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res 61: 7404-7407
43. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett JM, Finlay JL, Sposto R (2002) Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346: 420-427
44. Rubio M-P, von Deimling A, Yandell DW, Wiestler OD, Guisella JF, Louis DN (1993) Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 53: 3465-3467
45. Radner H, Blumcke I, Reifenberger G, Wiestler OD (2002) [The new WHO classification of tumors of the nervous system 2000. Pathology and genetics]. Pathologe 23: 260-283
46. Sarkar C, Ralte AM, Sharma MC, Mehta VS (2002) Recurrent astrocytic tumours - a study of p53 immunoreactivity and malignant progression. Br J Neurosurg 16: 335-342
47. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
48. Sembritzki O, Hagel C, Lamszus K, Deppert W, Bohn W (2002) Cytoplasmic localization of wild-type p53 in glioblastomas correlates with expression of vimentin and glial fibrillary acidic protein. Neurooncology 4: 171-178
49. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis H (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76: 428-434
50. Sidransky D, Mikkelsen T, Schwechhekner K, Rosenblum M, Cavanee W, Vogelstein B (1992) Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-847
51. Skomedal H, Kristensen GB, Lie AK, Holm R (1999) Aberrant expression of the cell cycle associated proteins TP 53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol 73: 223-228
52. 1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 91: 5320-5324
53. Soini Y, Niemela A, Kamel D, Herva R, Bloigu R, Paakko P, Vahakangas K (1994) p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. APMIS 102: 786-792
54. Tedeschi-Blok N, Schwartzbaum J, Lee M, Miike R, Wrensch M (2001) Dietary calcium consumption and astrocytic glioma: The San Francisco Bay Area Adult Glioma Study, 1991-1995. Nutr Cancer - An Int J 39: 196-203
55. Therneau TM, Grambsch PM, Fleming TR (1990) Martingale-based residuals and survival models. Biometrika 77: 147-160
56. Tuck SP, Crawford L (1989) Overexpression of normal human p53 in established fibroblasts leads to their tumorigenic conversion. Oncogene Res 4: 81-96
57. Werness BA, Levine AJ, Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79
58. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M (2002) History of allergies among adults with glioma and controls. Int J Cancer 98: 609-615
59. Zhang W, Shay JW, Deisseroth A (1993) Inactive p53 mutants may enhance the transcriptional activity of wild-type p53. Cancer Res 53: 4772-4775